Copy to clipboard 
OrthoPediatrics (KIDS) posted 4Q17 revenue of US $11.7MM, +23.7% vs. 4Q16, and 2017 revenue of $45.6MM, +22.4% vs. 2016.
| 4Q17 | 4Q16 | $ Change | % Change | |
| Trauma | $8.5 | $6.7 | $1.8 | 26.9% |
| Spine | $2.9 | $2.4 | $0.5 | 20.8% |
| Arthroscopy/Soft Tissue Repair | $0.3 | $0.3 | -$0.1 | -17.8% |
| Total | $11.7 | $9.4 | $2.2 | 23.7% |
| 2017 | 2016 | $ Change | % Change | |
| Trauma | $32.8 | $26.9 | $6.0 | 22.2% |
| Spine | $11.6 | $9.3 | $2.3 | 24.2% |
| Arthroscopy/Soft Tissue Repair | $1.2 | $1.1 | $0.1 | 12.4% |
| Total | $45.6 | $37.3 | $8.4 | 22.4% |
KIDS now refers to its spine segment as Scoliosis, and ACL/Other as Sports Medicine/Other. (We will continue to use our general market segment terms.)
Growth was driven in part by a move from stocking distributors in select geographies to a sales agency model, which KIDS considers to be a core strength in U.S. sales. Overall, the company ended 2017 with a 75+ member dedicated rep salesforce.
Five products were launched in 2017, including a wrist fusion plate in 4Q. For 2018, new product launches will include a small stature Response scoliosis plate, small stature BandLoc polyester sublaminar banding system, an osteogenesis imperfecta nail, next-gen PediNail and a pediatric foot system. The annual investment in consigned sets will increase from $3.5MM to $10MM, this year. An active growing implant system and spinal tethering products are in development.
For 2018, leadership offered revenue guidance of +22% vs. 2017, which would be $55.7MM.
KIDS leadership indicates that scoliosis competition continues from DePuy Synthes and Medtronic, but claims to see very little in trauma and deformity.
Source: OrthoPediatrics Corp.
OrthoPediatrics (KIDS) posted 4Q17 revenue of US $11.7MM, +23.7% vs. 4Q16, and 2017 revenue of $45.6MM, +22.4% vs. 2016.
Q17
Q16
$ Change
% Change
Trauma
$8.5
$6.7
$1.8 ...
OrthoPediatrics (KIDS) posted 4Q17 revenue of US $11.7MM, +23.7% vs. 4Q16, and 2017 revenue of $45.6MM, +22.4% vs. 2016.
| 4Q17 | 4Q16 | $ Change | % Change | |
| Trauma | $8.5 | $6.7 | $1.8 | 26.9% |
| Spine | $2.9 | $2.4 | $0.5 | 20.8% |
| Arthroscopy/Soft Tissue Repair | $0.3 | $0.3 | -$0.1 | -17.8% |
| Total | $11.7 | $9.4 | $2.2 | 23.7% |
| 2017 | 2016 | $ Change | % Change | |
| Trauma | $32.8 | $26.9 | $6.0 | 22.2% |
| Spine | $11.6 | $9.3 | $2.3 | 24.2% |
| Arthroscopy/Soft Tissue Repair | $1.2 | $1.1 | $0.1 | 12.4% |
| Total | $45.6 | $37.3 | $8.4 | 22.4% |
KIDS now refers to its spine segment as Scoliosis, and ACL/Other as Sports Medicine/Other. (We will continue to use our general market segment terms.)
Growth was driven in part by a move from stocking distributors in select geographies to a sales agency model, which KIDS considers to be a core strength in U.S. sales. Overall, the company ended 2017 with a 75+ member dedicated rep salesforce.
Five products were launched in 2017, including a wrist fusion plate in 4Q. For 2018, new product launches will include a small stature Response scoliosis plate, small stature BandLoc polyester sublaminar banding system, an osteogenesis imperfecta nail, next-gen PediNail and a pediatric foot system. The annual investment in consigned sets will increase from $3.5MM to $10MM, this year. An active growing implant system and spinal tethering products are in development.
For 2018, leadership offered revenue guidance of +22% vs. 2017, which would be $55.7MM.
KIDS leadership indicates that scoliosis competition continues from DePuy Synthes and Medtronic, but claims to see very little in trauma and deformity.
Source: OrthoPediatrics Corp.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
